All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

A number of large epidemiologic studies have demonstrated an independent association between serum uric acid (SUA) levels and risk of myocardial infarction (MI), heart failure, stroke, and cardiovascular mortality.\[[@pone.0192788.ref001]--[@pone.0192788.ref003]\] Elevated SUA is hypothesized to cause increased oxidative stress, microinflammation, lipid oxidation, and inhibition of nitric oxide production. In turn, these all contribute to endothelial dysfunction, microvascular ischemia, interstitial fibrosis, and myocardial dysfunction.\[[@pone.0192788.ref004]--[@pone.0192788.ref006]\]

Coronary flow reserve (CFR)---the ratio of peak hyperemic myocardial blood flow (MBF) over MBF at rest as measured by positron emission tomography (PET)--is a robust and reproducible clinical measure of the integrated hemodynamic effects of epicardial coronary artery stenoses, diffuse atherosclerosis, vessel remodeling, endothelial dysfunction, and microvascular dysfunction on myocardial tissue perfusion.\[[@pone.0192788.ref007],[@pone.0192788.ref008]\] A reduced CFR can be a sign of flow-limiting coronary artery stenoses as it is associated with the overall extent and severity of angiographic coronary artery disease (CAD).\[[@pone.0192788.ref009]\] Furthermore, a reduced CFR can indicate the presence of coronary vascular dysfunction involving smaller vessels, which increases the severity of inducible myocardial ischemia and sub-clinical myocardial injury beyond the effects of upstream coronary obstruction.\[[@pone.0192788.ref010]\] Importantly, there is growing, consistent evidence that impaired CFR is independently and incrementally associated with risk for MI, heart failure as well as cardiovascular death.\[[@pone.0192788.ref007],[@pone.0192788.ref008],[@pone.0192788.ref011],[@pone.0192788.ref012]\]

Over the past decades, the association between hyperuricemia and cardiovascular disease has been extensively studied. The association between SUA and increased cardiovascular risk appears to be only partially accounted by traditional coronary risk factors. This suggests that other mechanisms may contribute to the association between the SUA and increased cardiovascular risk. One such mechanism may involve the potential adverse effect of SUA on vascular function and in particular endothelial function, thereby increasing the potential for coronary vasoconstriction and thrombosis. To date, the direct effect of hyperuricemia on coronary vascular function, as assessed by CFR, has not been studied. We therefore conducted a cross-sectional study to evaluate coronary vascular function related to SUA levels in patients referred for stress myocardial perfusion PET. In addition, we examined whether the relationship between SUA levels and coronary vascular function differed by presence of diabetes based on the close relationship between hyperuricemia, gout and diabetes.\[[@pone.0192788.ref013]--[@pone.0192788.ref017]\]

Methods {#sec006}
=======

Study cohort {#sec007}
------------

All patients clinically referred for stress myocardial perfusion PET at the Brigham and Women's Hospital in Boston, Massachusetts, USA between January 2006 and March 2014 were eligible for inclusion. Of those, we selected patients with at least one SUA level measurement during the 180-day period before or after the PET test date. In patients with multiple PET tests during the study period, we included the study closest to the date of SUA level measurement. The study protocol was approved by the Institutional Review Board of the Brigham and Women's Hospital which granted a waiver of informed consent.

Definition of exposure and outcome {#sec008}
----------------------------------

SUA level measured by enzymatic colorimetric assay in 180 days before or after the PET test was the exposure of interest. Hyperuricemia was defined as ≥7 mg/dl in men and ≥6 mg/dl in women.

The primary outcomes of interest were stress MBF and CFR quantified using PET. Absolute MBF in milliliter/minute/gram (ml/min/g) was computed from the dynamic rest and stress imaging series with commercially available software (Corridor4DM; INVIA Medical Imaging Solution, Ann Arbor, MI) and previously validated methods.\[[@pone.0192788.ref018],[@pone.0192788.ref019]\] CFR was calculated as the ratio of absolute MBF at stress over rest for the entire left ventricle. CFR \<2 is known to be associated with worse cardiovascular outcomes in a general referral population.\[[@pone.0192788.ref011]\]

PET imaging {#sec009}
-----------

Following standard imaging protocols, patients were studied with a whole-body PET/computed tomography scanner (Discovery RX or STE LightSpeed 64, GE Healthcare, Milwaukee, WI) after at least 4 hours of fasting. Patients refrained from caffeine- and methylxanthine-containing substances and drugs for 24 hours before their scans. Briefly, at rest, radionuclide imaging was obtained with an intravenous bolus administration of ^13^N-ammonia or ^82^rubidium. Then, a standard intravenous infusion of a vasodilator (i.e., dipyridamole, adenosine, or regadenoson) or dobutamine was given for pharmacologic stress. At peak stress, a second dose of ^13^N-ammonia or ^82^rubidium was injected, and images were recorded in the same manner. MBF was measured during rest and peak stress with ^13^N-ammonia or ^82^rubidium as a perfusion tracer, as described previously.\[[@pone.0192788.ref018]--[@pone.0192788.ref021]\] Heart rate, blood pressure, and 12-lead ECG were recorded at baseline and every minute during and after pharmacological stress. Left ventricular ejection fraction at rest and stress were calculated from gated myocardial perfusion images with commercially available software. In addition, summed rest score, summed stress score, and summed difference score (stress minus rest) were computed, with higher scores reflecting larger areas of myocardial scar, scar plus ischemia, or ischemia, respectively; summed stress scores ≤3 are generally considered normal.\[[@pone.0192788.ref022]--[@pone.0192788.ref024]\]

Covariates {#sec010}
----------

We assessed a number of pre-defined variables potentially related to hyperuricemia or coronary vascular function based on patient interview and/or medical record data in the Partners Healthcare Research Patient Data Registry from the 180-day period immediately before or after the PET test date. These variables were: age and sex; body mass index; comorbidities including gout, hypertension, diabetes, smoking, coronary artery disease, heart failure, and dyslipidemia; medications including beta blockers, calcium channel blockers, nitrates, angiotensin-converting enzyme inhibitors, diuretics, gout-related medications (*i*.*e*., allopurinol, febuxostat and colchicine), and aspirin; and laboratory data including SUA, serum creatinine, LDL cholesterol and C-reactive protein levels.

Statistical analysis {#sec011}
--------------------

Patient characteristics were compared between the hyperuricemia and normouricemia groups. Statistical significance was assessed with Wilcoxon rank sum tests or two-sided t-tests for continuous variables and Fisher's exact or chi^2^ tests for binary variables. Normality was assessed using a combination of the Shapiro-Wilk test and visual inspection of descriptive statistics and histograms. Because data were not normally distributed, we used natural log transformation of SUA levels, CFR and MBF in all regression models. Pearson correlation was checked between log SUA, log CFR and log stress MBF. As diabetes is a strong predictor of coronary vascular function and CAD,\[[@pone.0192788.ref025]\] we tested for an interaction between SUA (as a continuous variable) and diabetes (yes/no) on CFR or stress MBF. Neither interaction was statistically significant. For primary analysis, we used unadjusted and multivariable linear regression models to examine the association between SUA levels and coronary vascular function in the main cohort. Our final models were adjusted for age, sex, summed stress score (i.e., a strong indicator of myocardial scar and ischemia), serum creatinine, and presence of gout diagnosis. Because prior myocardial scar or ischemia is a major determinant of CFR, we conducted a sensitivity analysis in which we performed multivariable linear regression models only in patients with summed stress scores ≤3.\[[@pone.0192788.ref022]--[@pone.0192788.ref024]\] We also performed stratified analysis by the presence of diabetes. All analyses were performed using SAS 9.3 Statistical Software (SAS Institute Inc., Cary, NC).

Results {#sec012}
=======

Cohort characteristics {#sec013}
----------------------

We identified a total of 382 patients including 208 with hyperuricemia and 174 with normouricemia. [Table 1](#pone.0192788.t001){ref-type="table"} presents patient characteristics. Mean (SD) age was 68.4 (12.4) years and 36% were female. Mean (SD) SUA level was 7.2 (2.6) mg/dl and 29% had gout. Cardiovascular comorbidities were prevalent as 85% had hypertension, 27% CAD and 11% heart failure. Diabetes was present in 44%, and 23% had any use of allopurinol or febuxostat.

10.1371/journal.pone.0192788.t001

###### Study cohort characteristics.

![](pone.0192788.t001){#pone.0192788.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  N                                                                Overall                  Hyperuricemia            Normouricemia            p-value
  ---------------------------------------------------------------- ------------------------ ------------------------ ------------------------ -------------
  Uric acid level, mg/dl                                           7.2 ± 2.6\               9.0 ± 2.1\               5.1 ± 1.2\               **\<0.001**
                                                                   7.0 \[5.4, 8.7\]         8.5 \[7.4, 10.1\]        5.3 \[4.5, 6.0\]         

  Age, years                                                       68.4 ± 12.4\             68.9 ± 12.0\             67.8 ± 12.9\             0.398
                                                                   69.0 \[60.0, 77.0\]      69.0 \[60.0, 78.0\]      69.0 \[60.0, 76.0\]      

  Female                                                           36                       37                       34                       0.68

  Body mass index, kg/m^2^                                         29.0 \[25.0, 34.0\]      29.0 \[26.0, 36.0\]      28.0 \[24.0, 33.0\]      0.08

  ***Comorbidities***                                                                                                                         

  Hypertension                                                     85                       91                       78                       **0.001**

  Diabetes                                                         44                       50                       37                       **0.012**

  Gout                                                             29                       39                       18                       **\<0.001**

  Smoking                                                          6                        6                        7                        0.641

  Coronary artery disease                                          27                       28                       26                       0.682

  Heart failure                                                    11                       16                       4                        **\<0.001**

  Dyslipidemia                                                     75                       77                       72                       0.242

  Serum creatinine, mg/dl [^a^](#t001fn003){ref-type="table-fn"}   1.2 \[0.9, 1.9\]         1.4 \[1.1, 2.1\]         1.0 \[0.8, 1.4\]         **\<0.001**

  LDL level, mg/dl [^b^](#t001fn004){ref-type="table-fn"}          79.0 \[58.0, 97.0\]      79.0 \[57.0, 97.0\]      78.0 \[61.0, 100.0\]     0.721

  ***Medications***                                                                                                                           

  Beta blockers                                                    69                       71                       66                       0.318

  Calcium channel blockers                                         26                       32                       20                       **0.008**

  Nitrates                                                         19                       24                       13                       **0.008**

  ACE inhibitors                                                   40                       39                       42                       0.519

  Diuretics                                                        47                       59                       33                       **\<0.001**

  Aspirin                                                          66                       67                       65                       0.6

  Statins and other lipid lowering drugs                           71                       74                       68                       0.205

  Colchicine                                                       8                        13                       3                        **\<0.001**

  Xanthine oxidase inhibitors                                      23                       30                       14                       **\<0.001**

  ***Cardiac function***                                                                                                                      

  Heart rate at rest, per minute                                   70.0 \[63.0, 80.0\]      71.0 \[63.0, 79.5\]      69.0 \[62.0, 80.0\]      0.312

  Systolic blood pressure at rest, mmHg                            142.0 \[127.0, 162.0\]   142.0 \[127.0, 163.0\]   142.0 \[125.0, 161.0\]   0.638

  LVEF at rest, %[^c^](#t001fn005){ref-type="table-fn"}            53.0 \[40.0, 62.0\]      50.0 \[35.0, 62.0\]      56.0 \[45.0, 63.0\]      **0.004**

  LVEF at stress, %[^d^](#t001fn006){ref-type="table-fn"}          57.0 \[44.0, 67.0\]      55.0 \[39.0, 64.0\]      61.0 \[47.0, 70.0\]      **0.001**

  Sum stress score                                                 4.0 \[0.0, 14.0\]        6.0 \[0.0, 16.0\]        2.0 \[0.0, 11.0\]        **0.004**

  Sum difference score                                             1.0 \[0.0, 6.0\]         2.0 \[0.0, 6.0\]         0.0 \[0.0, 5.0\]         0.155

  Sum rest score                                                   0.0 \[0.0, 6.0\]         0.0 \[0.0, 7.0\]         0.0 \[0.0, 3.0\]         **0.003**

  Myocardial blood flow at rest, mL/min/g                          1.0 \[0.8, 1.2\]         0.9 \[0.7, 1.2\]         1.0 \[0.8, 1.3\]         0.055

  Myocardial blood flow at stress, mL/min/g                        1.5 \[1.1, 2.1\]         1.4 \[1.0, 2.0\]         1.6 \[1.2, 2.3\]         **0.003**

  Coronary flow reserve                                            1.6 \[1.2, 2.0\]         1.5 \[1.2, 1.9\]         1.6 \[1.2, 2.1\]         **0.04**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

SD: standard deviation, LDL: low density lipoprotein, ACE: angiotensin converting enzyme, LVEF: left ventricle ejection fraction

P-values are for the comparisons between hyperuricemia and normouricemia.

^a^ Missing in \<1% of the hyperuricemia group and 2% of the normouricemia group

^b^ Missing in 20% of the hyperuricemia group and 22% of the normouricemia group

^c^ Missing in 3% of the hyperuricemia group and 2% of the normouricemia group

^d^ Missing in 2% of the hyperuricemia group and 6% of the normouricemia group

The mean (SD) uric acid level in milligram per deciliter was 9.0 (2.1) for the hyperuricemia group and 5.1 (1.2) for the normouricemia group. Hypertension, diabetes, heart failure, gout, and use of calcium channel blockers, nitrates, xanthine oxidase inhibitors, and diuretics were more common in patients with hyperuricemia. The patients with hyperuricemia had impaired renal function with median \[IQR\] serum creatinine of 1.4 \[1.1, 2.1\] mg/dl whereas the median \[IQR\] serum creatinine was normal in the normouricemia group (1.0, \[0.8, 1.4\]). Median LDL level was similar between the groups.

Coronary vascular function {#sec014}
--------------------------

The median \[IQR\] summed stress score was 4 \[0.0, 14\] for the overall cohort, 6.0 \[0.0, 16.0\] for the hyperuricemia, and 2.0 \[0.0, 11\] for the normouricemia group, indicating more prevalent myocardial damage in patients with hyperuricemia. 185 patients (48.4%) in the overall cohort had a normal summed stress score ≤3. Median \[IQR\] CFR was 1.6 \[1.2, 2.0\] and median \[IQR\] stress MBF was 1.5 \[1.1, 2.1\] ml/min/g in the overall cohort. The median CFR and stress MBF were lower (worse) in the hyperuricemia group versus the normouricemia group. There were weak negative correlations between SUA and CFR (r = -0.13, p = 0.015) and between SUA and MBF at stress (r = -0.24, p\<0.001) in the unadjusted analysis (see [S1](#pone.0192788.s001){ref-type="supplementary-material"} and [S2](#pone.0192788.s002){ref-type="supplementary-material"} Figs). At rest, the heart rate and systolic blood pressure were similar between the hyperuricemia and normouricemia groups, but left ventricular ejection fraction was lower in patients with hyperuricemia ([Table 1](#pone.0192788.t001){ref-type="table"}).

[Table 2](#pone.0192788.t002){ref-type="table"} presents the main results from the multivariable linear regression models. In the final multivariable linear regression model adjusting for age, sex, diabetes, summed stress score, serum creatinine and gout, SUA was associated with stress MBF (β = -0.14, p = 0.01), but not with CFR (β = -0.07, p = 0.14). In a sensitivity analysis limiting to 184 patients with a normal summed stress score (≤3), SUA was associated with both CFR (β = -0.14, p = 0.037) and stress MBF (β = -0.16, p = 0.048).

10.1371/journal.pone.0192788.t002

###### Association between serum uric acid level and coronary vascular function[\*](#t002fn002){ref-type="table-fn"}.

![](pone.0192788.t002){#pone.0192788.t002g}

  Outcome variable                       Model adjustment   Regression coefficient (Standard error)   p-value
  -------------------------------------- ------------------ ----------------------------------------- -------------
  All patients (n = 382)                                                                              
  Coronary flow reserve                  None               -0.12 (0.05)                              **0.015**
  Age and sex                            -0.11 (0.05)       **0.022**                                 
  Age, sex, diabetes, and SSS            -0.08 (0.05)       0.101                                     
  Age, sex, diabetes, SSS, and Cr        -0.05 (0.05)       0.255                                     
  Age, sex, diabetes, SSS, Cr and gout   -0.07 (0.05)       0.138                                     
  Myocardial blood flow at stress        None               -0.28 (0.06)                              **\<0.001**
  Age and sex                            -0.22 (0.06)       **\<0.001**                               
  Age, sex, diabetes, and SSS            -0.16 (0.05)       **0.002**                                 
  Age, sex, diabetes, SSS, and Cr        -0.15 (0.05)       **0.007**                                 
  Age, sex, diabetes, SSS, Cr and gout   -0.14 (0.05)       **0.01**                                  
  Patients with SSS≤3 (n = 184)                                                                       
  Coronary flow reserve                  None               -0.15 (0.06)                              **0.023**
  Age and sex                            -0.16 (0.07)       **0.016**                                 
  Age, sex, diabetes                     -0.16 (0.07)       **0.014**                                 
  Age, sex, diabetes, and Cr             -0.13 (0.06)       0.054                                     
  Age, sex, diabetes, Cr and gout        -0.14 (0.07)       **0.037**                                 
  Myocardial blood flow at stress        None               -0.23 (0.08)                              **0.003**
  Age and sex                            -0.19 (0.08)       **0.014**                                 
  Age, sex, diabetes                     -0.18 (0.08)       **0.019**                                 
  Age, sex, diabetes, and Cr             -0.15 (0.08)       **0.048**                                 
  Age, sex, diabetes, Cr and gout        -0.16 (0.08)       **0.048**                                 

SSS: summed stress score, Cr: serum creatinine

\*Log transformed values of serum uric acid level, coronary flow reserve, myocardial blood flow at stress, and serum creatinine were used

Stratified analysis {#sec015}
-------------------

Characteristics of the diabetic (n = 167) and non-diabetic (n = 215) subgroups are presented in Tables [3](#pone.0192788.t003){ref-type="table"} and [4](#pone.0192788.t004){ref-type="table"}. The mean age (SD) was 67.1 (10.3) years in the diabetic subgroup and 69.4 (13.8) in the non-diabetic subgroup. Median \[IQR\] BMI was 32.0 \[28.0, 38.0\] kg/m^2^ in the diabetes and 27.0 \[24.0, 31.0\] kg/m^2^ in the non-diabetes. Overall, patients with diabetes had higher prevalence of comorbidities including 38% with gout versus 22% with gout in the non-diabetic subgroup. 41.9% of the diabetic group and 53.5% of the non-diabetic group had a normal summed stress score. Median stress MBF was lower in the diabetic group but median CFR was the same in both diabetic and non-diabetic subgroups. In patients with diabetes (see [S1](#pone.0192788.s001){ref-type="supplementary-material"} and [S2](#pone.0192788.s002){ref-type="supplementary-material"} Figs), SUA was not correlated with either CFR (r = -0.02, p = 0.80) or MBF at stress (r = -0.13, p = 0.10) even in the unadjusted analysis. No association was noted in multivariable linear regressions ([Table 5](#pone.0192788.t005){ref-type="table"}**)**.

10.1371/journal.pone.0192788.t003

###### Characteristics of patients with diabetes.

![](pone.0192788.t003){#pone.0192788.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  N                                                                Overall                  Hyperuricemia            Normouricemia            p-value
  ---------------------------------------------------------------- ------------------------ ------------------------ ------------------------ -------------
  Uric acid level, mg/dl                                           7.6 ± 2.7\               9.2 ± 2.1\               5.1 ± 1.2\               **\<0.001**
                                                                   7.4 \[5.6, 9.3\]         8.9 \[7.6, 10.2\]        5.2 \[4.4, 6.1\]         

  Age, years                                                       67.1 ± 10.3\             68.4 ± 10.0\             65.0 ± 10.4\             **0.042**
                                                                   68.0 \[60.0, 75.0\]      68.0 \[61.0, 77.0\]      66.0 \[59.0, 73.0\]      

  Female                                                           34                       37                       28                       0.243

  Body mass index, kg/m^2^                                         32.0 \[28.0, 38.0\]      33.0 \[28.0, 39.0\]      31.5 \[27.5, 36.0\]      0.169

  ***Comorbidities***                                                                                                                         

  Hypertension                                                     90                       94                       84                       **0.037**

  Gout                                                             38                       47                       25                       **\<0.001**

  Smoking                                                          4                        4                        5                        1

  Coronary artery disease                                          30                       28                       33                       0.523

  Heart failure                                                    13                       18                       3                        **0.004**

  Dyslipidemia                                                     79                       80                       78                       0.819

  Serum creatinine, mg/dl [^a^](#t003fn003){ref-type="table-fn"}   1.3 \[1.0, 1.9\]         1.4 \[1.1, 1.9\]         1.1 \[0.9, 2.0\]         0.115

  LDL level, mg/dl [^b^](#t003fn004){ref-type="table-fn"}          79.0 \[56.0, 98.0\]      79.5 \[57.0, 98.0\]      76.0 \[55.0, 95.0\]      0.531

  ***Medications***                                                                                                                           

  Beta blockers                                                    73                       72                       75                       0.656

  Calcium channel blockers                                         29                       38                       16                       **0.002**

  Nitrates                                                         26                       30                       20                       0.163

  ACE inhibitors                                                   47                       43                       53                       0.19

  Diuretics                                                        56                       68                       36                       **\<0.001**

  Aspirin                                                          72                       74                       70                       0.625

  Statins and other lipid lowering drugs                           75                       75                       75                       0.972

  Colchicine                                                       13                       19                       3                        **\<0.001**

  Xanthine oxidase inhibitors                                      29                       36                       19                       **0.018**

  ***Cardiac function***                                                                                                                      

  Heart rate at rest, per minute                                   70.0 \[63.0, 80.0\]      71.0 \[64.0, 80.0\]      69.5 \[63.0, 80.0\]      0.567

  Systolic blood pressure at rest, mmHg                            143.0 \[125.0, 170.0\]   144.0 \[130.0, 172.0\]   139.0 \[122.0, 164.0\]   0.204

  LVEF at rest, %[^c^](#t003fn005){ref-type="table-fn"}            51.0 \[39.0, 62.0\]      50.5 \[35.0, 62.0\]      52.0 \[42.0, 60.0\]      0.53

  LVEF at stress, %[^d^](#t003fn006){ref-type="table-fn"}          54.0 \[40.0, 66.0\]      54.0 \[39.0, 65.0\]      55.0 \[44.5, 70.0\]      0.205

  Sum stress score                                                 6.0 \[0.0, 15.0\]        6.0 \[0.0, 15.0\]        4.5 \[0.0, 15.0\]        0.597

  Sum difference score                                             2.0 \[0.0, 7.0\]         3.0 \[0.0, 7.0\]         2.0 \[0.0, 8.0\]         0.864

  Sum rest score                                                   0.0 \[0.0, 6.0\]         1.0 \[0.0, 6.0\]         0.0 \[0.0, 7.0\]         0.362

  Myocardial blood flow at rest, mL/min/g                          0.9 \[0.7, 1.2\]         0.9 \[0.7, 1.2\]         0.9 \[0.8, 1.2\]         0.291

  Myocardial blood flow at stress, mL/min/g                        1.4 \[1.1, 2.1\]         1.5 \[1.0, 2.1\]         1.4 \[1.2, 1.8\]         0.709

  Coronary flow reserve                                            1.6 \[1.2, 2.1\]         1.5 \[1.2, 2.1\]         1.6 \[1.2, 2.0\]         0.683
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

SD: standard deviation, LDL: low density lipoprotein, ACE: angiotensin converting enzyme, LVEF: left ventricle ejection fraction

P-values are for the comparisons between hyperuricemia and normouricemia.

^a^ Missing in 0% of the hyperuricemia group and 2% of the normouricemia group

^b^ Missing in 17% of the hyperuricemia group and 17% of the normouricemia group

^c^ Missing in 5% of the hyperuricemia group and 2% of the normouricemia group

^d^ Missing in 1% of the hyperuricemia group and 6% of the normouricemia group

10.1371/journal.pone.0192788.t004

###### Characteristics of patients without diabetes.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  N                                                                Overall                  Hyperuricemia            Normouricemia            p-value
  ---------------------------------------------------------------- ------------------------ ------------------------ ------------------------ -------------
  Uric acid level, mg/dl                                           6.9 ± 2.5\               8.9 ± 2.0\               5.1 ± 1.2\               **\<0.001**
                                                                   6.7 \[5.3, 8.3\]         8.3 \[7.3, 9.9\]         5.3 \[4.6, 5.9\]         

  Age, years                                                       69.4 ± 13.8\             69.4 ± 13.7\             69.4 ± 14.0\             0.999
                                                                   70.0 \[60.0, 80.0\]      70.0 \[58.0, 79.0\]      71.0 \[60.0, 81.0\]      

  Female                                                           37                       36                       38                       0.763

  Body mass index, kg/m^2^                                         27.0 \[24.0, 31.0\]      27.0 \[25.0, 31.0\]      27.0 \[24.0, 31.0\]      0.554

  ***Comorbidities***                                                                                                                         

  Hypertension                                                     81                       88                       74                       **0.013**

  Gout                                                             22                       31                       14                       **0.002**

  Smoking                                                          8                        8                        8                        0.863

  Coronary artery disease                                          25                       28                       22                       0.343

  Heart failure                                                    9                        14                       5                        **0.015**

  Dyslipidemia                                                     71                       74                       68                       0.303

  Serum creatinine, mg/dl [^a^](#t004fn003){ref-type="table-fn"}   1.2 \[0.9, 1.7\]         1.4 \[1.0, 2.2\]         1.0 \[0.8, 1.2\]         **\<0.001**

  LDL level, mg/dl [^b^](#t004fn004){ref-type="table-fn"}          79.5 \[62.0, 95.5\]      79.0 \[58.0, 92.0\]      80.0 \[67.0, 101.0\]     0.421

  ***Medications***                                                                                                                           

  Beta blockers                                                    65                       70                       61                       0.169

  Calcium channel blockers                                         24                       26                       22                       0.526

  Nitrates                                                         14                       18                       9                        0.057

  ACE inhibitors                                                   36                       35                       36                       0.934

  Diuretics                                                        40                       50                       31                       **0.006**

  Aspirin                                                          61                       61                       61                       0.938

  Statins and other lipid lowering drugs                           68                       72                       63                       0.156

  Colchicine                                                       5                        7                        3                        0.295

  Xanthine oxidase inhibitors                                      17                       24                       11                       **0.012**

  ***Cardiac function***                                                                                                                      

  Heart rate at rest, per minute                                   70.0 \[62.0, 80.0\]      71.0 \[63.0, 79.0\]      69.0 \[61.0, 80.0\]      0.403

  Systolic blood pressure at rest, mmHg                            142.0 \[128.0, 158.0\]   140.0 \[125.0, 157.0\]   143.0 \[130.0, 158.0\]   0.427

  LVEF at rest, %[^c^](#t004fn005){ref-type="table-fn"}            55.0 \[42.0, 63.0\]      50.0 \[34.0, 62.0\]      57.0 \[46.0, 64.0\]      **0.003**

  LVEF at stress, %[^d^](#t004fn006){ref-type="table-fn"}          59.0 \[45.0, 68.0\]      55.0 \[39.0, 64.0\]      63.0 \[51.0, 70.0\]      **0.002**

  Sum stress score                                                 2.0 \[0.0, 13.0\]        5.0 \[0.0, 18.0\]        0.0 \[0.0, 7.0\]         **0.004**

  Sum difference score                                             0.0 \[0.0, 5.0\]         0.0 \[0.0, 6.0\]         0.0 \[0.0, 4.0\]         0.174

  Sum rest score                                                   0.0 \[0.0, 4.0\]         0.0 \[0.0, 7.0\]         0.0 \[0.0, 2.0\]         **0.004**

  Myocardial blood flow at rest, mL/min/g                          1.0 \[0.8, 1.3\]         0.9 \[0.8, 1.2\]         1.0 \[0.8, 1.3\]         0.166

  Myocardial blood flow at stress, mL/min/g                        1.6 \[1.1, 2.1\]         1.4 \[1.1, 1.9\]         1.8 \[1.2, 2.5\]         **\<0.001**

  Coronary flow reserve                                            1.6 \[1.2, 1.9\]         1.5 \[1.2, 1.7\]         1.7 \[1.3, 2.2\]         **0.002**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

SD: standard deviation, LDL: low density lipoprotein, ACE: angiotensin converting enzyme, LVEF: left ventricle ejection fraction

P-values are for the comparisons between hyperuricemia and normouricemia.

^a^ Missing in 1% of the hyperuricemia group and 2% of the normouricemia group

^b^ Missing in 23% of the hyperuricemia group and 25% of the normouricemia group

^c^ Missing in 2% of the hyperuricemia group and 3% of the normouricemia group

^d^ Missing in 4% of the hyperuricemia group and 6% of the normouricemia group

10.1371/journal.pone.0192788.t005

###### Association between serum uric acid level and coronary vascular function for patients stratified by diabetes[\*](#t005fn002){ref-type="table-fn"}.

![](pone.0192788.t005){#pone.0192788.t005g}

  Outcome variable                      Model adjustment   Regression coefficient (Standard error)   p-value
  ------------------------------------- ------------------ ----------------------------------------- -------------
  *With diabetes*                                                                                    
  **Coronary flow reserve**             None               -0.02 (0.08)                              0.803
  Age and sex                           -0.01 (0.08)       0.876                                     
  Age, sex, SSS and Cr                  0.01 (0.07)        0.856                                     
  Age, sex, SSS, Cr and gout            -0.003 (0.08)      0.969                                     
  **Myocardial blood flow at stress**   None               -0.15 (0.09)                              0.1
  Age and sex                           -0.14 (0.09)       0.111                                     
  Age, sex, SSS, and Cr                 -0.11 (0.08)       0.187                                     
  Age, sex, SSS, Cr and gout            -0.10 (0.08)       0.242                                     
  *Without diabetes*                                                                                 
  **Coronary flow reserve**             None               -0.21 (0.06)                              **0.001**
  Age and sex                           -0.20 (0.06)       **0.003**                                 
  Age, sex, SSS, and Cr                 -0.14 (0.07)       **0.038**                                 
  Age, sex, SSS, Cr and gout            -0.15 (0.07)       **0.022**                                 
  **Myocardial blood flow at stress**   None               -0.37 (0.08)                              **\<0.001**
  Age and sex                           -0.27 (0.08)       **\<0.001**                               
  Age, sex, SSS and Cr                  -0.19 (0.07)       **0.01**                                  
  Age, sex, SSS, Cr and gout            -0.19 (0.07)       **0.01**                                  

SSS: summed stress score, Cr: serum creatinine

\*Log transformed values of serum uric acid level, coronary flow reserve, myocardial blood flow at stress, and serum creatinine were used.

However, among patients with no diabetes, SUA (see [S1](#pone.0192788.s001){ref-type="supplementary-material"} and [S2](#pone.0192788.s002){ref-type="supplementary-material"} Figs) had a negative correlation with both CFR (r = -0.22, p = 0.001) and stress MBF (r = -0.31, p\<0.001) in the unadjusted analysis. In multivariable linear regression adjusting for age, sex, summed stress score (a measure of the extent of myocardial scar and ischemia), serum creatinine and diagnosis of gout, a higher SUA remained modestly associated with a lower CFR (β = -0.15, p = 0.02) and stress MBF (β = -0.19, p = 0.01).

Discussion {#sec016}
==========

The potential causal role of SUA on CAD and other cardiometabolic diseases has been under debate over the past few decades. While a number of epidemiologic studies showed positive associations between SUA and CAD or cardiovascular disease,\[[@pone.0192788.ref001]--[@pone.0192788.ref003]\] Mendelian randomization studies did not find a causal role of SUA in CAD, cardiovascular disease or diabetes.\[[@pone.0192788.ref026],[@pone.0192788.ref027]\] In this cross-sectional study of 382 patients with a wide range of SUA levels, we demonstrated an inverse association between SUA and coronary vascular function in patients with no or minimal myocardial scar or ischemia (i.e., summed stress score ≤3) or those without diabetes, but no association among diabetic patients. The degree of association between SUA and coronary vascular function in non-diabetic patients was modest with a beta-coefficient of -0.15 for CFR and -0.19 for MBF in the multivariable linear regression models.

This present study provides one of the most comprehensive evaluations of myocardial perfusion and coronary vascular function in relation to SUA levels. We examined not only the overall relationship between SUA and coronary vascular function in patients with and without prior myocardial scar or ischemia, but also the relationship stratified by the presence of diabetes. Since not all patients with high SUA have gout, an independent risk factor for cardiovascular disease, our analysis was adjusted for the presence of gout. As a result, we noted a modest negative association between SUA and coronary vascular dysfunction in patients without overt CAD (i.e., normal summed stress score) and those without diabetes, but not in the diabetic group. The lack of a significant association in diabetic patients may be explained by the fact that the modest effect of SUA on CFR seen in non-diabetic patients is likely overshadowed by the known strong association of diabetes and associated metabolic abnormalities (hyperglycemia and insulin resistance) with coronary microvascular dysfunction.\[[@pone.0192788.ref025],[@pone.0192788.ref028]\] In other words, even if SUA has a modest causal role in determining coronary vascular function, the effect of SUA on coronary vascular function in diabetic patients may be too subtle. The observed difference in the association of SUA with coronary vascular dysfunction by diabetes may be also related to the greater prevalence of other comorbid conditions and/or use of cardiovascular medications in diabetic patients versus non-diabetic patients, which can be directly or indirectly related to coronary vascular dysfunction. While our findings need to be confirmed, it is worth investigating the longitudinal effect of SUA on coronary vascular dysfunction in patients with and without diabetes separately.

Another potential explanation for the difference in the association of SUA with coronary vascular dysfunction by diabetes may be related to the difference in the severity of underlying CAD between the diabetic and non-diabetic groups in the study cohort. In the diabetic group, 41.9% had a normal summed stress score (i.e., ≤3) while 53% did in the non-diabetic group. As seen in the sensitivity analysis limited to those with a normal summed stress score (≤3), SUA unlikely has a role in determining coronary vascular function in patients with established myocardial damages even if SUA is causally related to CAD.

This study has limitations. First, as discussed earlier, this study is based at a single academic center, in which the study patients were referred for a PET test for a clinical reason. Thus, the results may not be generalizable to those with hyperuricemia and no clinical symptoms of CAD or subtle CAD. Second, as this is a cross-sectional study, the causal relationship between SUA levels and coronary vascular function cannot be determined. Some patients may maintain high SUA levels for a long time unless they are treated. However, to reduce exposure misclassification (i.e., SUA level) in the study cohort, we required all the SUA levels to be drawn within 6 months from the PET test. Third, while the final models were adjusted for several important predictors of CAD risk including age, sex, renal function, gout diagnosis, and a summed stress score (i.e., a marker of myocardial scar and ischemia), there may be residual confounding. Fourth, this study is the first and largest study that investigated an association between SUA and coronary vascular function using a cardiac PET, but further confirmation of our results is necessary in a larger and more generalizable setting.

In conclusion, this cross-sectional analysis showed a modest inverse association between high SUA levels and coronary vascular function in patients without diabetes after adjusting for age, sex, serum creatinine, gout diagnosis and the extent and severity of perfusion defects. Such association was not noted in patients with diabetes. While our results need to be confirmed in different settings, this present study suggests that the effect of hyperuricemia on coronary vascular function or CAD differs by diabetes status and may be more evident in patients without diabetes. Furthermore, this study highlights the need for future research on the association between the change in SUA and the change in coronary vascular function over time, particularly in patients without diabetes.

Supporting information {#sec017}
======================

###### Pearson correlations between serum uric acid levels and myocardial blood flow (MBF) at stress.
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